CBP-1039

CBP-1039 is a bispecific antibody-drug conjugate (ADC) being developed by Coherent Biopharma for the treatment of solid cancers. It is built upon the company's proprietary Bi-XDC (bi-targeting ligand-drug conjugate) technology platform, which is designed to deliver bioactive molecules specifically to tumor cells by targeting two distinct antigens. CBP-1039 carries a topoisomerase inhibitor payload, a class of chemotherapy that interferes with DNA replication and transcription, leading to cell cycle arrest and apoptosis. While the specific cell-surface targets for CBP-1039 remain undisclosed, the bispecific nature of the conjugate is intended to enhance tumor selectivity and therapeutic index compared to traditional mono-targeting ADCs.